ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

Endocrine Abstracts (2019) 63 P1070 | DOI: 10.1530/endoabs.63.P1070

Childhood-onset growth hormone deficiency: evaluation after reaching final adult height

Radvilę Dobrovolskytę1,2, Rūta Navardauskaitė1,2,3 & Rasa Verkauskienė2,4,5


1Lithuanian University of Health Science, Kaunas, Lithuania; 2Department of Endocrinology, Hospital of Lithuanian University of Health Sciences, Kauno klinikos, Kaunas, Lithuania; 3Institute of Endocrinology, Lithuanian University of Health Sciences, Kaunas, Lithuania; 4Lithuanian university of Health Science, Kaunas, Lithuania; 5Institute of Endocrinology, Lithuanian University of Health Sciences, Kaunas, Lithuania.


Introduction: Growth hormone (GH) has multiple metabolic effects in adulthood, pointing to the need of identify those patients who would benefit of GH treatment after achievement of final height.

Objective: To assess GH secretion, bone mineral density (BMD) and metabolic profile in patients with childhood-onset GH deficiency (GHD) after completion of recombinant GH (rGH) therapy for linear growth.

Methodology: One hundred eleven patients (59 males) with childhood-onset GHD were investigated in 2007–2018 at least 3 months after discontinuation of rGH treatment. Permanent GHD was diagnosed when GH peak was less than 10 mU/l during GH stimulation test with insulin and less than 6 mU/l with glucagon. Fasting glycemia, insulin concentration and lipid profile were also assessed. Insulin resistance index (HOMA-IR) was calculated with formula: fasting glycemia (mmol/l) × fasting insulin concentration (mU/l) / 22.5. Bone mineral density (BMD) was determined by dual-energy x-ray absorptiometry (DXA) method (with Hologic Densitometer QDR4500A).

Results: Mean age of patients at the time of retesting was 16.2±1.3, [median 16.33; min 11.4; max 19.6] years. 76 patients had isolated GHD and 35 - multiple pituitary hormone deficiency, – 13 of them PROP1 gene mutation was identified. Twenty four patients (21.6%) have been diagnosed with permanent GHD (4 (5.2%) in the isolated GHD and 20 (57%) in MPHD patients, (P=0.001) and 87 (78.4%) – with transient GHD. Patients with permanent GHD achieved a greater final height compared with transient GHD (−0.4±1.4 vs. −1.4±0.9, respectively, P=0.003). Hypercholesterolemia was significantly more frequent in patients with permanent GHD compared to the transient GHD group (38.9% vs. 6.8%, respectively, P<0.01), HOMA-IR was significantly higher in the group of transient GHD (42.9 vs. 6.7; P=0.009). BMI and BMD were comparable in patients with permanent and transient GHD groups.

Conclusions: 21.6% of patients with childhood-onset GHD were found to have permanent GHD: 5.2% among patients with isolated and 57% in patients with MPHD. Patients with permanent GHD have reached a higher final height than patients with transient GHD. Patients with transient GHD were more insulin resistant, while those with permanent GHD had significantly higher cholesterol levels.

Article tools

My recent searches

No recent searches.